drugset / Trial / NCT00119652

Seroquel in Bipolar Depression Versus SSRI

NCT00119652

Phase 3 Completed 676 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.

Timeline

Start
2005-05
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg
Subject Quetiapine Small molecule 300 mg
Subject Quetiapine Small molecule 600 mg

Indications